Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Ma

Showing results (161-170 of 357) with videos related to

Pageof 36
Sort By:
Inflammatory Bowel Diseases|September 11, 2019
Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's DiseaseJohn George, Siddharth Singh, Parambir S Dulai, et al.
Journal of Crohn'S & Colitis|June 21, 2014
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort studyChristopher Ma, Vivian Huang, Darryl K Fedorak, et al.
Journal of Clinical Gastroenterology|November 13, 2014
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of ResponseChristopher Ma, Vivian Huang, Darryl K Fedorak, et al.
Gastroenterology|October 3, 2020
Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide AnalysisChristopher Ma, Stephen E Congly, Kerri L Novak, et al.
Digestive Diseases (Basel, Switzerland)|September 27, 2023
Considerations for Colorectal Neoplasia Detection in Inflammatory Bowel Disease Clinical TrialsMira M Yang, Keith Usiskin, Harris A Ahmad, et al.
The American Journal of Gastroenterology|February 9, 2023
Patients With Crohn's Disease and Permanent Ileostomy Are Universally Excluded From Clinical Trials: A Systematic ReviewSudheer K Vuyyuru, Florian Rieder, Virginia Solitano, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Identifying Outcomes in Clinical Trials of Pouchitis for the Development of a Core Outcome SetChristopher Ma, Jonathan Athayde, Sarah C Davies, et al.
Drugs|July 29, 2019
Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art ReviewWillemijn E de Rooij, Evan S Dellon, Claire E Parker, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 17, 2019
Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidenceTal Engel, Diana E Yung, Christopher Ma, et al.
Inflammatory Bowel Diseases|December 22, 2023
Characteristics of Interventional Trials for Patients Living With Intestinal Stoma Registered in ClinicalTrials.gov With a Focus on Inflammatory Bowel DiseaseSudheer K Vuyyuru, Christopher Ma, Tanmay Sharma, et al.
Pageof 36

Showing results (161-170 of 357) with videos related to

Sort By:
Pageof 36
Inflammatory Bowel Diseases|September 11, 2019
Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's DiseaseJohn George, Siddharth Singh, Parambir S Dulai, et al.
Journal of Crohn'S & Colitis|June 21, 2014
Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort studyChristopher Ma, Vivian Huang, Darryl K Fedorak, et al.
Journal of Clinical Gastroenterology|November 13, 2014
Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of ResponseChristopher Ma, Vivian Huang, Darryl K Fedorak, et al.
Gastroenterology|October 3, 2020
Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide AnalysisChristopher Ma, Stephen E Congly, Kerri L Novak, et al.
Digestive Diseases (Basel, Switzerland)|September 27, 2023
Considerations for Colorectal Neoplasia Detection in Inflammatory Bowel Disease Clinical TrialsMira M Yang, Keith Usiskin, Harris A Ahmad, et al.
The American Journal of Gastroenterology|February 9, 2023
Patients With Crohn's Disease and Permanent Ileostomy Are Universally Excluded From Clinical Trials: A Systematic ReviewSudheer K Vuyyuru, Florian Rieder, Virginia Solitano, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2018
Identifying Outcomes in Clinical Trials of Pouchitis for the Development of a Core Outcome SetChristopher Ma, Jonathan Athayde, Sarah C Davies, et al.
Drugs|July 29, 2019
Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art ReviewWillemijn E de Rooij, Evan S Dellon, Claire E Parker, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 17, 2019
Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidenceTal Engel, Diana E Yung, Christopher Ma, et al.
Inflammatory Bowel Diseases|December 22, 2023
Characteristics of Interventional Trials for Patients Living With Intestinal Stoma Registered in ClinicalTrials.gov With a Focus on Inflammatory Bowel DiseaseSudheer K Vuyyuru, Christopher Ma, Tanmay Sharma, et al.
Pageof 36